Company Overview and News
valleyforge_final.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT COMPANY Investment Company Act file number: 811-58431 Name of Registrant: Vanguard Valley Forge Funds Address of Registrant: P.O. Box 2600 Valley Forge, PA 19482 Name and address of agent for service: Heidi Stam, Esquire P.
institutionalindex_final.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT COMPANY Investment Company Act file number: 811-06093 Name of Registrant: Vanguard Institutional Index Funds Address of Registrant: P.O. Box 2600 Valley Forge, PA 19482 Name and address of agent for service: Heidi Stam, Esquire P.
index_final.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT COMPANY Investment Company Act file number: 811-02652 Name of Registrant: Vanguard Index Funds Address of Registrant: P.O. Box 2600 Valley Forge, PA 19482 Name and address of agent for service: Heidi Stam, Esquire P.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number 811-21774 First Trust Exchange-Traded Fund (Exact name of registrant as specified in charter) 120 East Liberty Drive, Suite 400 Wheaton, IL 60187 (Address of principal executive offices) (Zip code) W.
AJS Bancorp, Inc. reports preliminary financial results for the quarter ended June 30, 2015.We analyze the earnings along side the following peers of AJS Bancorp, Inc. – MidSouth Bancorp, Inc., BancFirst Corporation, AmeriServ Financial, Inc. and American National Bankshares Inc. (MSL-US, BANF-US, ASRV-US and AMNB-US) that have also reported for this period.HighlightsSummary numbers: Revenues of …
Stocks have suddenly gone cold in November. This has brought the market back to a key inflection point at a time when underlying fundamentals are challenged. Today's market is not without meaningful e
MidSouth Bancorp is up ~15% since putting in lows shortly after Q1'15 reporting in early-May.This is in the face of a tough macro market and some cautious color from MidSouth CEO Rusty Cloutier on the
With so much recent focus on oil & natural gas commodity pricing crashes, are we forgetting the other large player in the ecosystem? The lenders?Yes, the exposure is often fragmented between lending s
MidSouth Bancorp reported a terrible quarter, which should be a warning to those still long the stock.MSL's massive loan book is heavily weighted to oil services companies - the hardest hit of the oil
IBKC was a calculated risk that I advised Seeking Alpha PRO readers to take just two months ago, and it has paid out 7.6% ex. dividends.Now, however, with heightened macroeconomic risk in IBKC's immed
A notable disconnect has recently unfolded in the oil market.Oil prices have rolled back over since early March to reach fresh new cycle lows.But selected regional banks that had followed the oil pric
Concerns about loans made to oil companies by energy-friendly regional banks are overblown, Raymond James analysts say, viewing the risk of material credit losses as unlikely given the conservative u
This is how problems in an industrial sector spread across an economy.It has been no secret that the energy sector has been under heavy pressure due to the precipitous decline in oil prices since last
Dallas-based Comerica (CMA -1.3%) is an outlier to the downside among the regional names as oil tumbles another 3.7% to the lowest level since the summer of 2009.Other lenders with sizable Texas-
Philip van Doorn puts together a list of 15 lenders with sizable Texas operations, ranked by their exposure to energy credit as a percent of total loans:MidSouth Bancorp (NYSE:MSL), BOK Financial (NAS
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
2018-05-17 - Asif
Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...